ArticleClinical case reports2019
Primary signet ring cell carcinoma of the pancreatic head: A case report.
Article in Clinical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Primary pancreatic signet ring cell carcinoma: molecular mechanisms and advances in clinical diagnosis and treatment.World journal of surgical oncology · 2025Review
- Primary pancreatic signet ring cell carcinoma: a case series from China and literature review.Discover oncology · 2025Article
- Is programmed death-ligand 1 positivity a predictor of poor survival in patients with different histological subtypes of pancreatic cancer?CytoJournal · 2025Article
- A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Therapeutic advances in medical oncology · 2024Review
- Article
- Multivisceral resection for primary pancreatic signet ring cell carcinoma.Clinical journal of gastroenterology · 2023Article
- Survival analysis and individualized prediction of survival benefit for pancreatic signet ring cell carcinoma: a population study based on the SEER database.BMC gastroenterology · 2023Article
- Prognosis prediction and comparison between pancreatic signet ring cell carcinoma and pancreatic duct adenocarcinoma: a retrospective observational study.Frontiers in endocrinology · 2023Observational
- Epidemiology and prognostic analysis of patients with pancreatic signet ring cell carcinoma: a population-based study.BMC gastroenterology · 2022Article
- Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature.Journal of pancreatic cancer · 2021Review
- Primary signet ring cell carcinoma of the pancreatic head: A case report.Clinical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.